血管性血友病因子裂解酶间隔区结构域突变对酶生物学功能的影响

doi:10.13481/j.1671-587X.20240403

Abstract

Abstract:

Objective To discuss the biological function of the spacer domain of ADAM metalloproteinase with thrombospondin type 1 motifs 13 （ADAMTS13） in the cleaving process of von Willebrand factor （vWF），and to clarify the role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura （TTP）. Methods The point mutation method was introduced sequentially into the amino acid residues TEDRLPR of the ADAMTS13 spacer domain （mutants M1－M7） by site-directed mutagenesis. The constructed ADAMTS13 and its mutants plasmids were transfected into the human embryonic kidney HEK293 cells， and the recombinant proteins were purified after stable expression. The cleavage capabilities of both wild type and mutant ADAMTS13 were observed under denaturation conditions， shear stress， and after treatment with ADAMTS13 antibodies. Results The fluorescence resonance energy transfer （FRET） assay results showed that compared with wild type ADAMTS13，the cleavage abilities of ADAMTS13 mutant M4 （R635A） and mutant M7 （R638A） on the FRET-vWF73 were decreased （P<0.05）. Under denaturation conditions， the wild-type ADAMTS13 could cleave the vWF multimers； compared with wild-type ADAMTS13， the cleavage activities of ADAMTS13 mutant M4 （R635A） and mutant M7 （R638A） were significantly decreased （P<0.01）. Under in vitro shear stress， compared with wild type ADAMTS13， the abilities of ADAMTS13 mutant M4 （R635A） and mutant M7 （R638A） to cleave vWF multimers were significantly decreased （P<0.01）. Compared with wild type ADAMTS13， the binding affinity between vWF and ADAMTS13 mutant M4 （R635A） and mutant M7 （R638A） had no significant difference （P>0.05）， indicating there were multiple binding sites between C-terminal of ADAMTS13 and vWF. The ADAMTS13 antibodies were able to inhibit the cleavage ability of both wild-type and mutant ADAMTS13 to some extent. Conclusion The activity of ADAMTS13 after spacer domain mutation is decreased. The ADAMTS13 mutant M4 （R635A） and mutant M7 （R638A） may be the important action sites for ADAMTS13 in substrate recognition.

Key words: Von Willebrand factor lyase, ADAM metalloproteinase with thrombospondin type 1 motifs 13, Spacer domain, Von Willebrand factor, Thrombotic thrombocytopenic purpura

CLC Number:

R554.6

Meng WANG,Hao WU,Hua LI,Yihong ZHAO,Shengyu JIN. Effect of ADAMTS13 spacer domain mutations on biological function of enzyme[J].Journal of Jilin University(Medicine Edition), 2024, 50(4): 900-907.

Figures/Tables 6

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Tab. 1

Fig. 5

References 21

1	FIDALGO T， MARTINHO P， PINTO C S， et al. Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing［J］. Res Pract Thromb Haemost， 2017， 1（1）： 69-80.
2	XIE X T， XIAO Y Y， ZHANG Y， et al. Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura［J］. J Thromb Thrombolysis， 2023， 55（2）： 399-405.
3	ERCIG B， ARFMAN T， HRDINOVA J， et al. Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity［J］. J Biol Chem， 2021， 297（4）： 101132.
4	TAYLOR A， VENDRAMIN C， OOSTERHOLT S， et al. Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura［J］. J Thromb Haemost， 2019， 17（1）： 88-98.
5	THOMPSON G L， KAVANAGH D. Diagnosis and treatment of thrombotic microangiopathy［J］. Int J Lab Hematol， 2022， 44（）： 101-113.
6	ROOSE E， SCHELPE A S， TELLIER E， et al. Open ADAMTS13， induced by antibodies， is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura［J］. Blood， 2020， 136（3）： 353-361.
7	SCULLY M. TTP： an open and shut （closed） case［J］. Blood， 2020， 136（3）： 265-266.
8	ZHENG X L， WU H M， SHANG D Z， et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura［J］. Haematologica， 2010， 95（9）： 1555-1562.
9	THOMAS M R， GROOT R D， SCULLY M A， et al. Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura［J］. EBioMedicine， 2015， 2（8）： 942-952.
10	WAELE L D， CURIE A， KANGRO K， et al. Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP［J］. Blood Adv， 2021， 5（21）： 4480-4484.
11	JIN S Y， SKIPWITH C G， ZHENG X L. Amino acid residues Arg（659）， Arg（660）， and Tyr（661） in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor［J］. Blood， 2010， 115（11）： 2300-2310.
12	XIE X T， XIAO Y Y， ZHANG Y， et al. Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura［J］. J Thromb Thrombolysis， 2023， 55（2）： 399-405.
13	HALKIDIS K， ZHENG X L. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura［J］. J Thromb Haemost， 2022， 20（10）： 2197-2203.
14	PLAUTZ W E， RAVAL J S， DYER M R， et al. ADAMTS13： origins， applications， and prospects［J］. Transfusion， 2018， 58（10）： 2453-2462.
15	吴昊，李华，苏畅，等. 血管性血友病因子裂解酶CysR结构域生物学功能的研究［J］. 中国实验血液学杂志， 2021， 29（3）： 893-900.
16	AI J H， SMITH P， WANG S W， et al. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor［J］. J Biol Chem， 2005， 280（33）： 29428-29434.
17	SELVAKUMAR S， LIU A， CHATURVEDI S. Immune thrombotic thrombocytopenic purpura： spotlight on long-term outcomes and survivorship［J］. Front Med， 2023， 10： 1137019.
18	彭一，张榕. 药物相关血栓性微血管病的发病机制与诊治［J］. 中国实用内科杂志， 2023， 43（6）： 457-460.
19	SCHIEPPATI F， RUSSO L， MARCHETTI M， et al. Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse： a multi-institutional study［J］. Am J Hematol， 2020， 95（8）： 953-959.
20	李树君，金圣宇. 血管性血友病因子裂解酶在血栓性血小板减少性紫癜中的作用研究进展［J］. 延边大学医学学报， 2022， 45（1）： 55-59.
21	COLONNE C K， FAVALORO E J， PASALIC L. The intriguing connections between von willebrand factor， ADAMTS13 and cancer［J］. Healthcare， 2022， 10（3）： 557.

ADAMTS13	B_max	K_d(×10^－6mol^－1)	B_max/K_d(×10^－3mol^－1)
WT	0.66±0.06	13.81±1.20	47.61
M1	0.43±0.06	13.36±1.50	32.01
M2	0.70±0.08	11.25±1.80	61.95
M3	0.56±0.07	14.14±1.90	39.78
M4	0.74±0.09	18.97±1.70	38.79
M5	0.56±0.07	12.93±2.20	43.61
M6	0.52±0.06	12.75±1.90	40.95
M7	0.45±0.05	12.74±1.80	35.19
B_max：Maximum binding capacity；K_d：Dissociation constant；WT：wild type ADAMTS13；M1：T632A；M2：E633A；M3：D634A；M4：R635A；M5：L636A；M6：P637A；M7：R638A.

Effect of ADAMTS13 spacer domain mutations on biological function of enzyme

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 21

Related Articles 1

Metrics

Comments

Recommended 10